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RESEARCH ARTICLE
Infectious Disease

Type I IFN Signaling Protects Mice from Lethal SARS-CoV-2
Neuroinvasion
Md Bashir Uddin,* Yuejin Liang,* Shengjun Shao,* Sunil Palani,* Michael McKelvey,† Scott C. Weaver,* and Keer Sun*
*Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; and †Department of Experimental Pathology, University of
Texas Medical Branch, Galveston, TX

Multiple organ damage is common in patients with severe COVID-19, even though the underlying pathogenic mechanisms remain
unclear. Acute viral infection typically activates type I IFN (IFN-I) signaling. The antiviral role of IFN-I is well characterized in vitro.
However, our understanding of how IFN-I regulates host immune response to SARS-CoV-2 infection in vivo is incomplete. Using a
human ACE2-transgenic mouse model, we show in the present study that IFN-I receptor signaling is essential for protection against
the acute lethality of SARS-CoV-2 in mice. Interestingly, although IFN-I signaling limits viral replication in the lung, the primary
infection site, it is dispensable for efficient viral clearance at the adaptive phase of SARS-CoV-2 infection. Conversely, we found that in
the absence of IFN-I receptor signaling, the extreme animal lethality is consistent with heightened infectious virus and prominent
pathological manifestations in the brain. Taken together, our results in this study demonstrate that IFN-I receptor signaling is required
for restricting virus neuroinvasion, thereby mitigating COVID-19 severity. ImmunoHorizons, 2022, 6: 716–721.

INTRODUCTION
The pandemic coronavirus SARS-CoV-2 warrants critical investigation of fundamental pathogenic mechanisms. Type I IFNs
(IFN-Is), particularly IFN-a/b, are often recognized as key innate
cytokines for limiting virus replication and promoting adaptive
immune response during acute infection (13). The inhibitory
effect of IFN-Is on SARS-CoV-2 replication is well characterized in vitro (1, 48); however, our understanding of their role
in vivo during COVID-19 pathogenesis remains incomplete.
It has been shown in African green monkeys that SARS-CoV-2
induces localized and sustained upregulation of IFN transcriptomic
pathways in the lung as compared with the quickly resolved systemic responses (9). In a mouse model based on adeno-associated

virusmediated expression of human angiotensin Iconverting
enzyme-2 (hACE2), it has been suggested that IFN-I receptor
signaling does not control SARS-CoV-2 replication, but rather
drives pathological responses (10). In line with this, IFN-I has
been suggested to be involved in COVID-19 pathology in multiple other studies (1113).
To determine how IFN-I signaling regulates the immune
balance between viral control and pathological response during
SARS-CoV-2 infection in vivo, we have developed an hACE2transgenic IFN-I receptor gene-deficient (hACE2Ifnar1!/!) mouse
model via cross breeding Ifnar1!/! mice with the K18-hACE2
strain. Using this human ACE2-transgenic mouse model, we
show that IFN-I receptor signaling is essential for protection
against COVID-19 lethality. Interestingly, hACE2Ifnar1!/! mice
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ABSTRACT
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are competent in T cell recruitment and viral control in the
lung. In contrast, we found that the hypersusceptibility of
hACE2Ifnar1!/! mice is associated with their heightened viral
burden and pathological manifestation in the brain. Taken together, our data in this study demonstrate that IFN-I signaling
is required for limiting virus neuroinvasion and acute animal
lethality after respiratory SARS-CoV-2 infection.
MATERIALS AND METHODS

Bronchoalveolar lavage cell analysis
Bronchoalveolar lavage fluid (BALF) samples were collected by
making an incision in the trachea and lavaging the lung twice
with 0.8 ml of PBS (pH 7.4). For flow cytometry analysis, BALF
cells were incubated with 2.4G2 mAb against FcgRII/III and
stained with allophycocyanin-conjugated anti-CD11c (BioLegend),
BV510-conjugated anti-CD11b (BioLegend), PE-Cy7conjugated
anti-Ly6G (clone 1A8, BioLegend), PerCP-Cy5.5conjugated antiLy6C (BioLegend), BV421-conjugated antiSiglec-F (BioLegend),
and PE-conjugated anti-TCRb mAbs. The stained cells were
fixed for 24 h in 2% paraformaldehyde before analyzing on a
MACSQuant Analyzer 10 and using FlowJo software for analysis.
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stained with H&E using standard methods. Whole-mount H&Estained lung tissues were scanned using a Leica Aperio LV1
scanner and software. Lung tissues were semiquantitatively
assessed at low power (×40) for the proportion of parenchyma
with alveoli containing intraluminal material in the background
of interstitial expansion and inflammation. Each lung was scored
by the relative amount of abnormal tissue as follows: 0, normal, 1,
125%; 2, 2650%; 3, 5175%; 4, >76% (15). Digital images were
generated using Leica Biosystems Aperio ImageScope 12.

Statistical analysis
Significant differences between experimental groups were
determined using an ANOVA analysis followed by a two-tailed
Student t test (to compare two samples) in GraphPad Prism 9
(GraphPad Software, La Jolla, CA). Survival analyses were performed using the log-rank test. For all analyses, a p value <0.05
was considered to be significant.
RESULTS

IFN-I receptor signaling attenuates COVID-19 lethality
To determine the role of IFN-I signaling in vivo, C57BL/6 WT,
Ifnar1!/!, K18-hACE2 (hACE2_WT), and hACE2Ifnar1!/!
mice were i.n. challenged with SARS-CoV-2 to induce animal
morbidity and mortality. In the absence of human ACE2 expression, C57BL/6WT and Ifnar1!/! mice did not exhibit any
morbidity after 1500 PFU/mouse of viral infection (Fig. 1A).
Conversely, this viral inoculum resulted in $25% weight loss
and "50% (LD50) mortality in hACE2_WT mice (Fig. 1B). At
the same time, hACE2Ifnar1!/! mice appeared to have delayed
weight loss compared with hACE2_WT controls (Fig. 1A);
nonetheless, their symptoms worsened and all hACE2Ifnar1!/!

FIGURE 1. Ifnar1 deficiency renders K18-hACE2 mice hypersusceptible
to SARS-CoV-2 infection.
(A–D) Body weights (mean 6 SE) and survival of C57BL/6 WT or

Histology analysis
Mice were euthanized 7 d after viral infection, and the lungs
and brains were collected and fixed in 10% neutral buffered
formalin solution for 7 d before histological analyses. Paraffinembedded tissues were sectioned to a thickness of 5 mm and
https://doi.org/10.4049/immunohorizons.2200065

Ifnar1!/! mice and hACE2-transgenic WT (hACE2_WT) and Ifnar1!/!
(hACE2Ifnar1!/!) mice after i.n. infection with (A and B) 1500 and (C and D)
300 PFU/mouse of SARS-CoV-2 virus. *p < 0.05, **p < 0.01, ***p < 0.001,
log-rank test. Data shown are representative of at least two independent
experiments.
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Murine model of SARS-CoV-2 infection
Specific pathogen-free C57BL/6 wild-type (WT), Ifnar1!/!, and
K18-hACE2 (14) mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and bred at the University of Texas
Medical Branch (UTMB) following Institutional Animal Care
and Use Committee guidelines. hACE2Ifnar1!/! mice were
generated by crossing Ifnar1!/! mice with the K18-hACE2
strain. Research conducted in this study was reviewed and
approved by UTMB Institutional Biosafety Committee, and all
animal experiments were carried out in accordance with UTMB
Assurance of Compliance with U.S. Public Health Service Policy
on Humane Care and Use of Laboratory Animals, which is on
file with the Office of Protection from Research Risks (National
Institutes of Health).
SARS-CoV-2 strain USA-WA1/2020 was provided by the
World Reference Center for Emerging Viruses and Arboviruses
and originally isolated by the Centers for Disease Control and
Prevention. COVID-19 was induced through intranasal (i.n.)
infection of anesthetized, sex- and age-matched adult mice with
USA-WA1/2020 at 300 or 1500 PFU/mouse in 50 ml of sterile
PBS. Titers of virus stocks and viral levels in the organs of
infected mice were determined by 50% tissue culture-infective
dose assays on Vero E6 cell monolayers. Animal body weight
and mortality were monitored twice daily until day 20 after viral
infection.
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animals succumbed to COVID-19 within 10 d (Fig. 1B). After a
lower dose (0.2LD50) of SARS-CoV-2 infection, hACE2_WT
mice exhibited reduced weight loss (<20%) and mortality as
compared with the LD50 infection (Fig. 1C, 1D). In contrast,
none of hACE2Ifnar1!/! mice was able to recover from this
low dose of viral infection, not even an apparent delay in time
to death (Fig. 1D). Taken together, these data indicate that
IFN-I receptor signaling is essential for host resistance to
COVD-19 lethality.

dispensable for ab T cell recruitment into the airway during
SARS-CoV-2 infection.
To determine whether IFN-I signaling is essential for controlling viral infection in the lung, we examined viral burdens
at days 4 and 7 after SARS-CoV-2 infection. Although there
were "2-fold increased viral titers in hACE2Ifnar1!/! lungs
compared with hACE2_WT controls at 4 dpi (Fig. 3A), both
groups of mice exhibited efficient lung viral clearance by 7 dpi
(Fig. 3B). These results suggest that although IFN-I signaling
contributes to initial inhibition of viral replication, it is not
essential for lung viral control at the adaptive phase of SARSCoV-2 infection.

IFN-I receptor signaling inhibits SARS-CoV-2 neuroinvasion
We wanted to examine whether IFN-I signaling is essential for
preventing SARS-CoV-2 systemic invasion, secondary to viral
replication in the lung. Therefore, we evaluated the viral load
in other organs after i.n. infection with 1500 PFU/mouse of
SARS-CoV-2. Infectious virus was barely detectable in the
spleen and kidney of both hACE2_WT and hACE2Ifnar1!/!
mice at 7 dpi (Fig. 3C, 3D), indicating that IFN-I signaling is
dispensable for preventing viral replication in these tissues.
SARS-CoV-2 has demonstrated neuroinvasive properties in
human patients and animal models, even though the underlying mechanism remains unclear (1723). In agreement with

FIGURE 2. Ifnar1 deficiency does not affect airway T cell recruitment
in response to SARS-CoV-2 infection.
(A) Flow cytometry analysis of BALF immune cells and (B and C) the

FIGURE 3. Ifnar1 deficiency is associated with severe neuroinvasion

numbers of alveolar macrophages (AMs), monocytes/DCs (Mos/DCs),

after SARS-CoV-2 infection.

polymorphonuclear neutrophils (PMNs), and NK1.11 and TCRb1 T cells

(A and B) Lung viral titers at 4 (A) and 7 (B) dpi. (C–E) Viral titers in the

in hACE2_WT and hACE2Ifnar1!/! airways at days 4 and 7 postinfection with 1500 PFU/mouse of SARS-CoV-2 virus. *p < 0.05, **p < 0.01,

spleen (C), kidney (D), and brain (E) at day 7 in hACE2_WT and
hACE2Ifnar1!/! mice after 1500 PFU/mouse of SARS-CoV-2 virus infec-

***p < 0.001, t test. Data shown are representative of two independent

tion. *p < 0.05, t test. Data shown are representative of two independent

experiments.

experiments.
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IFN-I receptor signaling is not essential for viral control in
the lung
We next assessed whether IFN-I signaling confers protection
by promoting acute antiviral immunity in the lung. It has been
shown that IFN-I signaling increases monocytes but inhibits
neutrophil recruitment during influenza virus infection (4, 16).
Interestingly, after SARS-CoV-2 infection, FACS analysis of
BALF cells revealed limited neutrophil (CD11b1Ly6G1) accumulation even in the absence of IFN-I signaling (Fig. 2). Nonetheless, compared with hACE2_WT controls, hACE2Ifnar1!/!
mice exhibited decreased infiltrating monocytes (CD11b1Ly6C1
and dendritic cells (DCs) (CD11c1Siglec-F!) in the airway
(Fig. 2B). The number of alveolar macrophages (CD11c1
Siglec-F1) was actually increased in hACE2Ifnar1!/! mice as
compared with hACE2_WT controls at 7 d postinfection (dpi).
Of note, hACE2Ifnar1!/! mice exhibited similar airway TCRb1
T cell infiltration as hACE2_WT controls, despite their decreased NK1.11 cells at 7 dpi (Fig. 2B, 2C). These findings suggest that IFN-I signaling promotes monocyte infiltration but is

ImmunoHorizons
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the lung.
(A) Lung histopathology (H&E) and (B) histopathologic scores (each symbol represents one mouse) of hACE2_WT (n 5 4) and hACE2Ifnar1!/!
mice (n 5 7) at day 7 after 300 PFU/mouse of SARS-CoV-2 infection.

that, we detected infectious virus in the brains at day 7 after
1500 PFU/mouse of SARS-CoV-2 infection (Fig. 3E). Interestingly,
the rate of neuroinvasion in hACE2_WT and hACE2Ifnar1!/!
mice was correlated with their differential mortality after this
high dose of infection. Furthermore, the viral load in the brains
of hACE2Ifnar1!/! mice was significantly higher than that in
hACE2_WT controls (Fig. 3E), indicating a more prominent viral
neuroinvasion and replication in the absence of IFN-I signaling.
Taken together, our data highlight that IFN-I has specific neuroprotective functions that inhibit SARS-CoV-2 neuroinvasion.

IFN-I receptor signaling attenuates SARS-CoV-2induced
brain pathology
It has been shown that IFN-I signaling attenuates inflammatory
lung damage and thereby improves host resistance to influenza

FIGURE 5. Ifnar1 deficiency is associated with prominent pathological manifestations in the brain.
(A and B) Representative brain histopathology (H&E) of hACE2_WT
(n 5 4) and hACE2Ifnar1!/! mice (n 5 7) at day 7 postinfection with
300 PFU/mouse of SARS-CoV-2 virus. Arrows indicate representative areas with multivacuolar structures (black) and neuropil vacuolation (red). Scale bars are indicated for each image.
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virus infection (1, 4). Thus, we investigated whether IFN-I signaling confers similar protection against lung pathology during
SARS-CoV-2 infection. Both hACE2_WT and hACE2Ifnar1!/!
mice exhibited pathological features in the lungs at day 7 after a
low dose (0.2LD50) of SARS-CoV-2 infection (Fig. 4A). Although
hACE2Ifnar1!/! mice tended to have aggravated lung injury,
their histopathological scores were not significantly different
from hACE2_WT controls (Fig. 4B). Thus, lung tissue damage
does not fully account for the acute death of hACE2Ifnar1!/!
mice after this low dose of SARS-CoV-2 infection.
Considering the extensive viral replication in the brains of
hACE2Ifnar1!/! mice, we then investigated whether IFN-I
signaling prevents SARS-CoV-2 neuroinvasion and therefore
direct damage to the CNS. Indeed, compared with hACE2_WT
controls, hACE2Ifnar1!/! mice exhibited more prominent histopathological manifestations in the brains, particularly neuropil
vacuolation and multivacuolar structures across brain cortex,
hippocampus, and striatum (Fig. 5). Thus, viral neuroinvasionassociated brain damage is likely the cause of acute lethality of a
low dose of SARS-CoV-2 in hACE2Ifnar1!/! mice.
DISCUSSION
In the current study, we have revealed a critical role of IFN-I
signaling in preventing SARS-CoV-2 neuroinvasion and brain
damage. IFN-I and IFN-stimulated genes have been identified
in the regulation of bloodbrain barrier (BBB) permeability and
the prevention of viral neuroinvasion in infectious mouse models
of West Nile virus, yellow fever virus, and rabies virus (2426).
During these neurotropic viral infections, IFN-I signaling
improves the antiviral response in the peripheral organs and
thereby restricts viral neuroinvasion. Accordingly, in the absence
of an intact IFN-I signaling pathway, an elevated level of viremia
in the periphery promotes virus transmission into the brain.
In this study, we show that during SARS-CoV-2 respiratory
infection, IFN-I signaling is dispensable for viral control in the
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FIGURE 4. SARS-CoV-2 infection induces pathological changes in
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